Lenalidomide enhances anti-myeloma cellular immunity

Cancer Immunology, Immunotherapy

Volumn 62, Issue 1, 2013, Pages 39-49

  Luptakova, Katarina ^a   Rosenblatt, Jacalyn ^a   Glotzbecker, Brett ^b   Mills, Heidi ^a   Stroopinsky, Dina ^a   Kufe, Turner ^a   Vasir, Baldev ^b   Arnason, Jon ^a   Tzachanis, Dimitri ^a   Zwicker, Jeffrey I ^a   Joyce, Robin M ^a   Levine, James D ^a   Anderson, Kenneth C ^b   Kufe, Donald ^b   Avigan, David ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Dendritic cell vaccine; Lenalidomide; Multiple myeloma; PD 1

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; LENALIDOMIDE; PROGRAMMED DEATH 1 RECEPTOR; STAT3 PROTEIN; STAT5 PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CD4 LYMPHOCYTE PERCENTAGE; CELL MEDIATED CYTOTOXICITY; CELL POLARITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL PROLIFERATION; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNOBLOTTING; LYMPHOCYTE ACTIVATION; MULTIPLE MYELOMA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; THALIDOMIDE;

EID: 84872487264     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1308-3     Document Type: Article

References (45)

1. Pratt G, Goodyear O, Moss P (2007) Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 138:563-579
2. Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793-800
3. Rosenblatt J, Glotzbecker B, Mills H et al (2011) PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 34:409-418
4. Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123-2132
5. Weber DM, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133-2142
6. Gay F, Hayman SR, Lacy MQ et al (2010) Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 115:1343-1350
7. Zonder JA, Crowley J, Hussein MA et al (2010) Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest oncology group trial (S0232). Blood 116:5838-5841
8. Attal M, Cances Lauwers V, Marit G et al (2010) Maintenance treatment with lenalidomide after transplantation for MYELOMA: final analysis of the IFM 2005-02 [abstract 310]. Blood (ASH Annual Meeting Abstracts) 116:310
9. McCarthy PL, Owzar K, Anderson KC et al (2010) Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract 37]. Blood (ASH Annual Meeting Abstracts) 116:37
10. Hideshima T, Chauhan D, Shima Y et al (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950
11. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085
12. Breitkreutz I, Raab MS, Vallet S et al (2008) Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22:1925-1932
13. Geitz H, Handt S, Zwingenberger K (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31:213-221
14. LeBlanc R, Hideshima T, Catley LP et al (2004) Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103:1787-1790
15. Hayashi T, Hideshima T, Akiyama M et al (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128:192-203
16. Görgün G, Calabrese E, Soydan E et al (2010) Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 116:3227-3237
17. Davies FE, Raje N, Hideshima T et al (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216
18. Galustian C, Meyer B, Labarthe MC et al (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58:1033-1045
19. Idler I, Giannopoulos K, Zenz T et al (2010) Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol 148:948-950
20. Lioznov M, El-Cheikh J Jr, Hoffmann F et al (2010) Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant 45:349-353
21. Spina F, Montefusco V, Crippa C et al (2011) Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. Leukemia Lymphoma 52:1262-1270
22. Tohnya TM, Hwang K, Lepper ER et al (2004) Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. J Chromatogr, B: Anal Technol Biomed Life Sci 811:135-141
23. Richardson PG, Blood E, Mitsiades CS et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458-3464
24. Blum W, Klisovic RB, Becker H et al (2010) Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 28:4919-4925
25. Vasir B, Borges V, Wu Z et al (2005) Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol 129:687-700
26. Yin L, Li Y, Ren J, Kuwahara H, Kufe D (2003) Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 278:35458-35464
27. Wei L, Laurence A, O'Shea JJ (2008) New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation. Semin Cell Dev Biol 19:394-400
28. Yao Z, Kanno Y, Kerenyi M et al (2007) Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109:4368-4375
29. Cohen AC, Nadeau KC, Tu W et al (2006) Cutting edge: decreased accumulation and regulatory function of CD4 + CD25(high) T cells in human STAT5b deficiency. J Immunol 177:2770-2774
30. Murawski MR, Litherland SA, Clare-Salzler MJ, Davoodi-Semiromi A (2006) Upregulation of foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis. Ann N Y Acad Sci 1079:198-204
31. Disis ML (2010) Immune regulation of cancer. J Clin Oncol 28:4531-4538
32. Neuber B, Herth I, Tolliver C et al (2011) Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T-cells from patients with multiple myeloma. J Immunol 187:1047-1056
33. Lee BN, Gao H, Cohen EN et al (2011) Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 117:3999-4008
34. Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM (2009) Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4 + Foxp3 + T-cells. Leukemia 23:605-607
35. Kneppers E, van der Holt B, Kersten MJ et al (2011) Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial. Blood 118:2413-2419
36. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M (2004) B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10:5094-5100
37. Zhang L, Gajewski TF, Kline J (2009) PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 114:1545-1552
38. Mumprecht S, Schürch C, Schwaller J, Solenthaler M, Ochsenbein AF (2009) Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 114:1528-1536
39. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293-12297
40. Benson DM Jr, Bakan CE, Mishra A et al (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel, monoclonal anti-PD-1 antibody. Blood 116:2286-2294
41. Gong J, Chen D, Kashiwaba M, Kufe D (1997) Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3:558-561
42. Gong J, Nikrui N, Chen D et al (2000) Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 165:1705-1711
43. Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S (2003) Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol 170:5317-5325
44. Rosenblatt J, Vasir B, Uhl L et al (2011) Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 117:393-402
45. Vasir B, Wu Z, Crawford K et al (2008) Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J Immunol 181:808-821